Tranexamic Acid

Hereditary Factor VIII Deficiency Disease With Inhibitor

Oslo University HospitalSmall moleculePhase 4 / ApprovedDormant

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

67 Active assets in the Hereditary Factor VIII Deficiency Disease With Inhibitor cohort.

Asset / Sponsor	Phase	Rating
Turoctocog Alfa Novo Nordisk A/S	Phase 4	A
Eptacog Alfa AryoGen Pharmed Co.	Phase 4	A
Rurioctocog Alfa Pegol Takeda	Phase 4	BBB
Immunoglobulin G4 [230-proline,de-449-lysine], anti-(human blood-coagulation factor IX)(human clone 0365-0001-9985 ?4-chain), disulfide with human clone 0365-0001-9985 ?-chain, (228?226?),(231?229?)-bis(disulfide) with anti-(human blood-coagulation factor X) immunoglobulin G4 [228-proline,405-leucine,409-lysine,de-447-lysine] (human clone 0365-0001-8174 ?4-chain) disulfide with human clone 0365-0001-8174 ?-chain Novo Nordisk A/S	Phase 3	BBB
Turoctocog Alfa Pegol Novo Nordisk A/S	Phase 3	BBB